Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multi-center, Open-label Study of IMGN779 Administered Intravenously in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia

NCT02674763 is registered in ClinicalTrials.gov with ImmunoGen, Inc. as lead sponsor.

NCT NCT02674763
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02674763 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multi-center, Open-label Study of IMGN779 Administered Intravenously in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia
Lead sponsor
ImmunoGen, Inc.
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2016
Completion date
July 31, 2019
Enrollment
62 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia